Table 2 Univariate analyses of baseline characteristics
Covariate | HR (95% CI) | p-value |
|---|---|---|
Age | 1.029 (1.001–1.058) | 0.04272 |
Sex | 2.018 (1.027–3.966) | 0.04175 |
ECOG PS | 1.924 (1.068–3.465) | 0.02932 |
T stage | 1.81 (1.026–3.193) | 0.04041 |
N stage | 1.111 (0.595–2.072) | 0.7419 |
M stage | 1.237 (0.599–2.557) | 0.5651 |
Underlying Hepatitis | 1.062 (0.512–2.202) | 0.8725 |
Cirrhosis | 2.25 (1.001–5.059) | 0.04976 |
Previous treatment | 0.555 (0.288–1.071) | 0.07916 |
Child-Pugh classification | 2.558 (1.454–4.501) | 0.001122 |
Radiation dose | 0.973 (0.921–1.028) | 0.3274 |
Types of PVTT | 1.151 (0.936–1.416) | 0.1822 |
Combined with sorafenib | 0.99 (0.968–1.013) | 0.4064 |
Additional treatment after SBRT | 0.999 (0.998–1) | 0.1453 |
Tumour maximum diameter | 0.971 (0.82–1.151) | 0.7344 |
AFP | 1 (1–1) | 0.03041 |
PLT | 1.001 (0.996–1.005) | 0.8191 |
HGB | 0.978 (0.962–0.995) | 0.009121 |
TBIL | 1.008 (0.997–1.019) | 0.1405 |
ALB | 0.906 (0.849–0.968) | 0.003482 |
ALT | 0.997 (0.993–1.002) | 0.2489 |
AST | 1 (0.998–1.001) | 0.5813 |